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Abstract: Human African trypanosomiasis is a neglected parasitic disease for which the current
treatment options are quite limited. Trypanosomes are not able to synthesize purines de novo and
thus solely depend on purine salvage from the host environment. This characteristic makes players
of the purine salvage pathway putative drug targets. The activity of known nucleoside analogues
such as tubercidin and cordycepin led to the development of a series of C7-substituted nucleoside
analogues. Here, we use RNA interference (RNAi) libraries to gain insight into the mode-of-action
of these novel nucleoside analogues. Whole-genome RNAi screening revealed the involvement of
adenosine kinase and 4E interacting protein into the mode-of-action of certain antitrypanosomal
nucleoside analogues. Using RNAi lines and gene-deficient parasites, 4E interacting protein was
found to be essential for parasite growth and infectivity in the vertebrate host. The essential nature
of this gene product and involvement in the activity of certain nucleoside analogues indicates that it
represents a potential novel drug target.
Keywords: trypanosomiasis; nucleoside analogues; RNAi; drug target; 4E-interacting protein
1. Introduction
Human African Trypanosomiasis (HAT), often referred to as sleeping sickness, is a
neglected tropical disease prevalent in the African continent in an area delineated by the
Sahara, Kalahari, and Namibian deserts [1]. The disease is caused by the human-infective
Trypanosoma brucei gambiense and T. b. rhodesiense, which are transmitted by tsetse flies [2].
The disease is characterized first by a haemolymphatic stage in which patients present
general flu-like symptoms such as fever, weight loss, and muscles aches. A meningo-
encephalitic stage subsequently develops when parasites have entered the central nervous
system and cause severe neurological symptoms and an altered sleep/wake cycle that is
characteristic of sleeping sickness [3].
Currently, available therapies are rather limited and have multiple shortcomings.
For example, pentamidine, suramin, melarsoprol, and nifurtimox/eflornithine combina-
tion therapy (NECT) require intravenous or intramuscular injections requiring patient
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hospitalization [4]. Additionally, these drugs exhibit problems of toxicity, with melarsoprol
being the most toxic, causing reactive encephalopathy in up to 5 per cent of stage-II HAT pa-
tients [5]. Recent encouraging developments in HAT treatment were the clinical trial results
for fexinidazole as the first oral monotherapy for g-HAT [6]. Fexinidazole has since then
been approved by the European Medicines Agency (EMA) and endorsed in the Democratic
Republic of Congo (DRC) for the treatment of both stages of HAT, although NECT remains
the treatment of choice for severely ill patients [7]. Nonetheless, for all antitrypanoso-
mal drugs, cases of drug resistance have already emerged in the field or were selected
experimentally, highlighting a continuous need for novel treatment strategies [8–10].
Given that the parasite lacks de novo purine synthesis and thus solely depends on
purine salvage [11], interaction with the involved pathways represents a valid strategy to
explore novel antitrypanosomal drugs. Nucleoside analogues such as tubercidin and cordy-
cepin were already proven active against T. brucei [12–15]. Tubercidin (7-deazaadenosine),
a nucleoside analogue produced by Streptomyces tubercidicus, exhibits potent activity against
a range of parasites [16–18], but is unfortunately extremely toxic to mammalian cells and
therefore of limited therapeutic value [14]. The potent activity of tubercidin (1) against
T. brucei inspired Hulpia et al. to explore a range of C7-substituted tubercidin analogues
(Figure 1). Substitution of 7-deazaadenosine with electron-poor phenyl groups gave rise to
a series of compounds showing micromolar activity. Replacement of the phenyl group by a
pyridine ring resulted in 5 exhibiting sub-micromolar antitrypanosomal activity and largely
reduced cytotoxicity compared to tubercidin [19]. A combination of structural elements
of tubercidin and cordycepin resulted in the development of 3′-deoxy-7-deazaadenosine
nucleosides, with 3′-deoxytubercidin (2) as the most promising candidate for late-stage
sleeping sickness [20]. Likewise, the screening of a series of 7-substituted 7-deazainosine
derivatives provided several 6-O-alkylated analogues (6–9) with nanomolar in vitro po-
tency and is thus interesting for further in vivo evaluation [21]. Another advantage of
nucleoside analogues is their high likelihood to cross the blood-brain barrier due to the
various purine transporters lining this barrier [22]. Sufficient compound exposure in the
central nervous system is essential for efficacy against stage-II of the disease and is a
requirement in the current target product profile [23].
Figure 1. An overview of the nucleoside analogues used in this study. Compound name (compound code). a 7-deaza
adenosine analogues. b inosine analogues. Compound codes in original publication: (Tubercidin (1), 3′-deoxytubercidin
(9)) [20], (TH1003 (31), FH6367, TH1008 (13)) [19], (FH8446 (23), FH9531 (36), FH9528 (24), FH10664 (28)) [21].
For most antitrypanosomal drugs, the mode-of-action (MoA) is not yet fully under-
stood setting hurdles for rational use in the field in view of the possible development
of drug resistance. Genome-wide RNA interference (RNAi) screening is a powerful tool
for the unbiased identification of genes involved in the MoA of novel compounds [24].
This technique has been applied to the current antitrypanosomal drugs confirming the
involvement of known drug targets, such as the amino acid transporter 6 (AAT6) for
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eflornithine and nitroreductase (NTR) for benznidazole and nifurtimox [25–28]. RNAi li-
braries of Trypanosoma were already extensively applied in procyclics [29–31]; however,
bloodstream forms (BSF) are the clinically relevant stage to study the MoA of drugs. Due to
their poor transformation efficiency, RNAi libraries in BSF have only emerged later [32–34].
In this study, we successfully applied whole-genome RNAi screening in combination
with confirmatory in vitro and in vivo approaches to identify genes participating in the
MoA of tubercidin analogues that may represent potential novel drug targets given their
essentiality for T. brucei infectivity.
2. Materials and Methods
2.1. Ethics Statement
The use of laboratory rodents was carried out in strict accordance with all mandatory
guidelines (EU directives, including the Revised Directive 2010/63/EU on the Protection
of Animals used for Scientific Purposes that came into force on 1 January 2013, and the
declaration of Helsinki in its latest version) and was approved by the Ethical Committee of
the University of Antwerp, Belgium (UA-ECD 2017-04).
2.2. Animals and Parasites
Female C57BL/6JRj were purchased from Janvier (Le Genest Saint Isle, France).
Food for laboratory rodents (Carfil, Arendonk, Belgium) and drinking water were available
ad libitum. The animals were kept in quarantine for at least 5 days before infection and
randomly allocated to the experimental units.
The RNAi library (kindly gifted by Professor Isabel Roditi, University of Bern) was
constructed in the New York “single marker” line, a derivative of MITat 1.2 BSF try-
panosomes [27]. Transfected EATRO1125 cells (wild-type (WT), 4E interacting protein
double knock-out (4EIP-KO), EIF4E1 double knock-out (4E1-KO), 4EIP add-back (4EIP-
AB), and EIF4E1 add-back (4E1-AB) containing a tetracycline-inducible 4EIP- or 4E1-myc
gene) [35] were available from the Clayton lab (University of Heidelberg).
2.3. Compounds
A range of tubercidin analogues (Figure 1) was synthetized as part of a campaign to find
novel hits with enhanced selective potency against T. brucei compared to tubercidin [19–21].
Experimental details regarding their synthesis are described [19–21]. The synthesis of ana-
logue 4 is described in Supplementary method S1. High activity to treat late-stage sleeping
sickness was demonstrated for 3′-deoxytubercidin (2) [20]. Substitution of C-7 with a bro-
mide, trifluoromethyl, or pyridin-2-yl group led to compounds 3–5, with the latter showing
sub-micromolar activity in vitro [19]. Compounds 6–9 are 7-substituted 7-deazainosine ana-
logues [21].
2.4. In Vitro Cytotoxicity Assay
Human lung fibroblasts (MRC-5SV2 cells) were cultured in Minimum Essential Medium
(MEM) (Life Technologies, Carlsbad, CA, United States) supplemented with L-glutamine,
NaHCO3, and 5% heat-inactivated fetal bovine serum (iFBS). Cells were seeded at a con-
centration of 15,000 cells/well, to which 4-fold dilutions of the test compounds were added
with 64 µM as the highest in-test concentration. After 72 h of drug exposure at 37 ◦C and 5%
CO2, cell viability was determined by fluorescence reading (Tecan®, GENios, Männedorf,
Switzerland) after a 4-h incubation with resazurin (Sigma Aldrich, St. Louis, MO, USA).
The 50% cytotoxic concentration (CC50) was calculated for each of the compounds.
2.5. Resazurin-Based Susceptibility Assay
T. brucei brucei MITat 1.2 New York “single marker” cells (NY-SM) were cultured in
Hirumi’s modified Iscove’s medium 9 (HMI-9) with 10% iFBS. To determine the in vitro
susceptibility, NY-SM were seeded at a concentration of 4000 parasites/well. Four-fold
dilutions of the test compounds were added with a highest in-test concentration of 64 µM.
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After 72 h of drug exposure at 37 ◦C and 5% CO2, the viability was determined by fluo-
rescence reading (Tecan®, GENios, Männedorf, Switzerland) after a 6-h incubation with
resazurin (Sigma Aldrich, St. Louis, MO, USA). The 50% inhibitory concentration (IC50)
was calculated by comparing cell viability to untreated control wells [36].
2.6. RNAi Library Screening
The RNAi library was cultured in 30 mL HMI-9 culture medium supplemented with
10% iFCS and 1 µg/mL tetracycline to induce the RNAi phenotype. Ten mL of culture
without tetracycline induction served as a negative control. After 62 h of induction, differ-
ent concentrations of 5 (400, 600, and 800 nM) were added to 10 mL of individual cultures
containing 1 × 105 cells/mL. The compound concentrations were based on their IC98/99
values as determined in the resazurin-based susceptibility assay. The cells were monitored
daily. As soon as the non-induced RNAi cultures collapsed and the induced cultures
grew normally under drug pressure, they were diluted 1:10 in a fresh medium containing
tetracycline and drug compound. After 2–3 passages, the cultures were harvested for
further analysis (Figure S1A).
2.7. RNAi Insert Identification
The genomic DNA (gDNA) of the drug-exposed parasites was isolated from 20 mL of a
stationary-phase culture using the QIAamp DNA mini kit (QIAGEN, Hilden, Germany). The
DNA concentration was determined using nanodrop and diluted to 20 ng/µL gDNA in PCR
water. The RNAi inserts were amplified using p2T7_seq (5′-CCGCTCTAGAACTAGTGGA-3′)
as forward and p2T7hygPJ4 (5′-GGAAAGCTAGCTTGCATGCCTG-3′) as reverse primer (PCR
program: 1 cycle for 1 min at 98 ◦C, 25 cycles for 1 min at 98 ◦C, 30 s at 58 ◦C, 1 min at 72 ◦C
and 1 cycle for 10 min at 72 ◦C).
PCR products were analyzed on a 1% agarose gel (100 V for 120′) to identify the
number and size of amplified inserts. PCR products were purified using the ExoSAP-ITTM
PCR Product Cleanup kit (ThermoFisher Scientific, Carlsbad, CA, USA). A nested PCR
was performed (PCR program: 1 cycle for 3 min at 94 ◦C, 30 cycles for 1 min at 94 ◦C,
1 min at 50 ◦C, 2 min and 30 s at 72 ◦C and 1 cycle for 10 min at 72 ◦C) and PCR products
were analyzed on a 1% agarose gel (100 V for 120′). Interesting inserts, only present in the
tetracycline clones, were extracted from the gel using the GenEluteTM Gel Extraction Kit
(Sigma-Aldrich, St. Louis, MO, USA).
Finally, the PCR products were ligated in the pCR 2.1 vector system (ThermoFisher
Scientific, Carlsbad, CA, USA) and transformed into high-efficiency competent E. coli
(NEB10) and plated onto LB agar with ampicillin. Five colonies per target were selected
to perform a colony PCR (PCR program: 1 cycle for 3 min at 94 ◦C, 30 cycles for 1 min at
94 ◦C, 1 min at 50 ◦C, 2 min and 3s at 72 ◦C and 1 cycle for 10 min at 72 ◦C) and were sub-
sequently analyzed on a 1% agarose gel (100 V for 120′). Positive clones were selected and
sequenced (VIB Genomics Core, Antwerp). The RNAi insert was sequenced bidirectionally
with primers p2T7_seq and p2T7linker_rev (5′-AGGGCCAGTGAGGCCTCTAGAG-3′).
Sequences were blasted against T. brucei transcripts on the TriTrypDB [37]. Retrieved trans-
lated sequences were subjected to characteristics determination using the ProtParam [38]
and SignalP tool [39] and homology detection using a comparison of hidden Markov
Models [40]).
2.8. Independent Confirmation of the RNAi Phenotype
To validate the RNAi effect of the different RNAi inserts, the insert was back-cloned
into a p2T7Bern vector for transformation into NY-SM cells (Figure S1B). The RNAi in-
serts were introduced together with Ndel and Xhol restriction sites in the PCR 2.1 vector
using P2T7_seq forward primer containing the NdeI site (GGAATTCCATATGCCGCTC-
TAGAACTAGTGGA) and the P2T7linker_rev reverse primer containing the XhoI site
(CCGCTCGAGAGGGCCAGTGAGGCCTCTAGAG). PCR products were analyzed on a
1.2% agarose gel and correct lanes were extracted from the gel using the GenEluteTM Gel
Microorganisms 2021, 9, 826 5 of 16
Extraction Kit (Sigma-Aldrich). The purified PCR product and the p2T7Bern vector were
digested overnight at 37 ◦C with NdeI and XhoI restriction enzymes. The digested DNA
was ligated using a T4 ligase for 2 h at room temperature. Finally, the ligated products
were transformed into high-efficiency competent E. coli (NEB10) by electroporation and
plated onto LB agar with ampicillin. A colony PCR was performed to identify the colonies
containing the vector followed by confirmation by sequencing.
Next, 10 µg of the P2T7Bern DNA containing the RNAi inserts was linearized with
NotI and purified using the QIAquick PCR purification kit (QIAGEN, Hilden, Germany);
4 × 107 NY-SM cells were transferred to a 2 mm gap cuvette together with 10 µg linear
plasmid DNA. The cells were subjected to two consecutive pulses of 1.2 kV with 186 Ω
resistance and 50 µF capacitance. After transformation, the cells were transferred to HMI-9
medium containing 10% iFCS. After 18–22 h, 2.5 µg/mL of hygromycin B was added to the
cells. After 6 days, the hygromycin B pressure was increased to 5 µg/mL. After sufficient
cell growth, the culture was used to generate monoclonal cell lines. Monoclonal lines
were subjected to resazurin-based susceptibility assays to determine the 50% inhibitory
concentration, as described above.
2.9. Efficiency of the RNAi Silencing
To determine the degree of knock-down of the different RNAi inserts after tetracycline
induction, an RT-qPCR was performed. The different RNAi clones were cultured in HMI-9
culture medium in the presence or absence of 1 µg/mL of tetracycline. Cultures were
diluted 1 in 10 every 24 h in fresh HMI-9 with or without tetracycline. After 68 h, RNA was
extracted using the RNA blood mini kit (QIAGEN, Hilden, Germany). cDNA was prepared
using the Tetro™ cDNA Synthesis Kit (Bioline). RT-qPCR was performed using the Sensi-
FAST™ SYBR® Hi-ROX Kit (Bioline) (PCR program: 1 cycle for 2 min at 95 ◦C, 40 cycles
for 5 s at 95 ◦C, 20 s at 60 ◦C, 15 s at 95 ◦C, 1 min at 60 ◦C and 15 s at 95 ◦C). TERT, Actin A,
and H2B were used as reference genes [41,42].
2.10. In Vitro Growth
The in vitro growth of RNAi clones was compared to the NY-SM background strain.
Parasites were seeded at a concentration of 4 × 105 cells/mL in 2 mL of HMI-9 with 10%
iFBS with or without the addition of 1 µg/mL tetracycline. Cell growth was monitored by
microscopic counting using a Neubauer improved haemocytometer for a period of 9 days.
Cells were diluted 1:5 daily.
2.11. Cell Cycle Analysis and RNA Quantification
NY-SM cells were exposed to different concentrations of 5 (corresponding to the IC50,
IC50/2, and IC50/5) for 24 h. For cell cycle analysis, the cells were harvested and washed
with PBS before staining with 5 µg/mL Hoechst 33,342 for 25 min at 37 ◦C. Cells were
analyzed on a MACSQuant flow cytometer (Miltenyi Biotec, Gladbach, Germany) using the
FlowJo X software package. For RNA quantification, extracts were made from a normalized
number of cells to correct for the impact of 5 on the number of recovered trypanosomes.
RNA was extracted using the QIAamp RNA blood mini kit (QIAGEN, Hilden, Germany).
Total RNA yields were determined using both Nanodrop 2000 spectrometry and Qubit
fluorimetric RNA content analysis. Additionally, specific transcripts in the RNA pool
were quantified using quantitative reverse transcription PCR (RT-qPCR) targeting the
spliced-leader RNA (SL-RNA), 18S rRNA, and transcripts encoding the telomerase reverse
transcriptase (TERT) (Table S1) [41,43].
2.12. Western Blot Analysis of PAD1
Tetracycline-induced 4EIP-AB parasites were seeded at a concentration of 5 ×
105 cells/mL and exposed to various concentrations of 5 and 3′-deoxytubercidin [20] (cor-
responding to the IC50, IC50/2 and IC50/5) for 48 h. Cells were resuspended in Laemmli
sample buffer (Bio-Rad, Hercules, CA, USA) containing β-mercaptoethanol. Genomic DNA
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was sheared by sonication and samples were stored at −80 ◦C until further analysis; 10 µL
of protein sample was loaded on 10% Mini-PROTEAN® TGX Stain-Free™ Protein Gel (Bio-
Rad) at 100 V. Proteins were transferred to a polyvinylidene difluoride (PVDF) membrane
at 100 V. Primary antibodies for PAD1 and EF1α (kindly gifted by Prof. Keith Matthews,
University of Oxford) were used at 1:1000 and 1:7000, respectively [44]. For protein detec-
tion, anti-rabbit (1:7000) or anti-mouse (1:1000) HRP-conjugated antibodies were used with
the Clarity Western ECL Substrate (Bio-Rad) detection system.
2.13. In Vivo Infectivity
Twelve female C57BL/6JRj were randomly divided into four groups. Two groups
(tetracycline-positive groups) were pre-treated for 48 h with 1 mg/mL of doxycycline
and 5% sucrose in the drinking water. Doxycycline exposure was maintained throughout
the entire experiment and fresh doxycycline solutions were prepared every 2–3 days.
The tetracycline-negative groups received water with 5% sucrose. On day 0, mice were
infected intraperitoneally with 5000 parasites. Each group was infected with a different
strain: NY-SM + (pre-induced with tetracycline in vitro), NY-SM—(not induced with
tetracycline), ADKIN A + (NY-SM cells transfected with RNAi insert Tb927.6.2300 and
pre-induced with tetracycline in vitro), and ADKIN A—(NY-SM cells transfected with
RNAi insert Tb927.6.2300 and not induced with tetracycline). Parasitaemia and anaemia
were determined using a Neubauer improved haemocytometer. To confirm adequate
knock-down of the genes of interest, 100 µL of blood was collected at day 4 post-infection
(dpi). RNA was extracted using the RNA blood mini kit (QIAGEN) and subjected to
RT-qPCR to determine the percentage of gene knock-down.
The role of 4EIP RNAi-mediated knockdown (NY-SM cells transfected with RNAi
insert Tb927.9.11050) and knockout (4EIP-KO and 4EIP-AB strains) in in vivo infectivity
was evaluated in a similar manner as described above.
2.14. Tsetse Fly Infections
T.b.b. AnTat1.1EPpyRE9 parasites were used to infect teneral tsetse flies (Glossina
morsitans morsitans) through a parasitized blood meal supplemented with 10 mM reduced
L-glutathione. The infected blood meal consisted of a mixture of infected mouse blood
(5–7 dpi) and defibrinated horse blood to obtain a final concentration of >106 BSF par-
asites/mL. Newly emerged tsetse flies were divided into three groups and offered an
infected blood meal with or without 5 or 3′-deoxytubercidin at a concentration correspond-
ing to the IC50. After the infected blood meal, tsetse flies were fed every 2–3 days with
uninfected defibrinated horse blood. At 7 dpi, tsetse flies were dissected to evaluate midgut
infection ratios.
2.15. Graphs and Statistical Analyses
All graphs and statistical analyses were prepared using GraphPad Prism 7 software.
3. Results
3.1. 7-Deaza Adenosine Analogues Act Independently of DNA and RNA Synthesis Inhibition
All 7-deaza adenosine analogues 2–9 showed sub-micromolar activity against T. brucei
parasites in vitro. Tubercidin was cytotoxic at low concentrations, as described in litera-
ture [45]. Analogues 4 and 9 showed a modest increase in selectivity, whereas the remaining
analogues showed a significantly improved selectivity (Table 1). Cell cycle analysis by flow
cytometry indicated no major impact on DNA synthesis (Figure 2A–D), suggesting that 5
does not inhibit the parasite’s DNA polymerase. The impact of various concentrations of 5
on RNA synthesis was analyzed next using standard quantification methods on the total
RNA extracts and specific RT-qPCR for quantitative detection of T. brucei SL-RNA, rRNA,
and TERT transcripts (Figure 2E–H). The results indicate that 5 does not act as a substrate
nor chain terminator for RNA synthesis given the absence of a major impact on the total
RNA pool and the levels of specific transcripts produced by RNA polymerase I and II.
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Table 1. Overview of the in vitro activity and cytotoxicity of the 7-deaza adenosine analogues on
NY-SM cells (IC50) and MRC-5 cells (CC50) [19–21].
Compound IC50 ± SEM (µM) CC50 ± SEM (µM) SI 1
Tubercidin (1) 0.12 ± 0.003 2.23 ± 0.68 18
3 0.38 ± 0.064 33.3 ± 12.6 88
4 0.38 ± 0.017 19.2 ± 15.2 50
5 0.15 ± 0.005 15.1 ± 4.1 103
6 0.05 ± 0.003 48 ± 16 960
7 0.08 ± 0.001 >64 800
8 0.10 ± 0.008 >64 640
9 0.10 ± 0.001 3.24 ± 0.01 32
1 The selectivity index (SI) represents the CC50/IC50. SEM: Standard Error of the Mean.
3.2. Involvement of Adenosine Kinase and 4E-Interacting Protein in the
Antitrypanosomal Activity
To determine the MoA of 5, selection of a genome-wide T. b. brucei RNAi library identified
four RNAi inserts (Table S2), most notably FLA1-binding protein (FLA1BP; Tb927.8.4050),
endonuclease G (EndoG; Tb928.8.4040), adenosine kinase (ADKIN; Tb927.6.2300), and 4E-
interacting protein (4EIP; Tb927.9.11050). To confirm the involvement of the different inserts in
the MoA of 5, the RNAi inserts were back-cloned into NY-SM cells. Two independent clones of
each RNAi insert were tested for their susceptibility to 5.
Out of the four knock-down constructs tested, only those silencing ADKIN and
4EIP exhibited an approximately 3-fold decrease in susceptibility to 5 (Figure 3). RT-qPCR
indicated variable gene silencing levels in the various RNAi clones, suggesting that residual
target activity may be responsible for the partial activity of the compound (Table 2).
For the RNAi clones FLA1BP and EndoG, no significant differences in susceptibility
could be observed between tetracycline-induced and non-induced clones. To confirm
these findings, the in vitro susceptibility assays were also conducted under continuous
tetracycline pressure, yielding similar results.
Figure 2. Cont.
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Figure 2. Effect of 5 on cell cycle regulation and RNA synthesis. (A) Gating strategy. (B) Results of the cell cycle analysis
after 24 h exposure to different concentrations of 5. Results of the cell cycle analysis (2N, S phase, 4N) expressed in total
cell numbers. (C) n = 2 and relative cell numbers. (D) n = 2. (E) Total RNA yield from trypanosomes exposed for 24 h
to different concentrations of 5 (n = 2). RNA content quantified using quantitative reverse transcription PCR (RT-qPCR)
specifically targeting SL-RNA. (F) n = 2 with two replicates, 18S rRNA. (G) n = 2 with two replicates and TERT mRNA.
(H) n = 2 with two replicates. RNA content and transcript levels are expressed as relative to the non-treated trypanosomes
(control). Error bars are SEM.
Figure 3. Drug susceptibility of RNAi clones targeting (A) ADKIN, (B) 4EIP, (C) FLA1BP, and (D) EndoG to 5. Results are
expressed as the mean IC50 (µM), and error bars represent SEM, and are based on at least two independent experiments
(n = 2), each with two biological replicates. + = tetracycline-induced clones; − = non-induced clones. All experiments were
performed with two independently generated RNAi clones. ** p < 0.01, *** p < 0.001, **** p < 0.0001 Kruskal–Wallis test
with Dunn’s multiple comparison test.
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Table 2. Overview of the RNA knock-down levels following in vitro induction with tetracycline.
% Knock-Down
Target Clone A 1 Clone B 1
FLABP1 44.1 ± 1.7 42.8 ± 0.6
EndoG 33.2 ± 0.9 31.0 ± 0.9
ADKIN 81.2 ± 0.2 83.4 ± 0.5
4EIP 85.0 ± 0.7 85.1 ± 0.3
1 Mean percentage knock-down compared to NY-SM cells ± standard error of mean.
3.3. 7-Deaza Adenosine Analogues Show a Variable Dependence on ADKIN and 4EIP
The susceptibility of ADKIN RNAi-mediated knockdown to other 7-deaza purine
analogues was evaluated in vitro. Four of the compounds showed a large decrease in
susceptibility (Figure 4) of which two (6 and 7) even completely lost their activity (up to the
highest concentration tested (64 µM)) against the ADKIN-knockdown strains. The large
dependency on ADKIN for antitrypanosomal activity proved particularly relevant for the
6-O-alkylated analogues 6–9 (Figure 4, red circles). For 4EIP, the susceptibility to other
7-deaza adenosine analogues was tested using both the RNAi-mediated knockdown and
knockout cell lines. Only 5 showed a partial dependence on 4EIP for its antitrypanosomal
activity (Figure 5). The effect seemed to be specific for 4EIP and not for the cap-binding
protein 4E1. The variable dependence of the different compounds on ADKIN and 4EIP
suggests a diverse MoA of the nucleoside analogues.
Figure 4. Susceptibility of ADKIN (A) and 4EIP (B). RNAi-mediated knockdown to compounds 1–4, and 6–9. Results are
expressed as the mean IC50 (µM), and error bars represent SEM and are based on at least two independent experiments
(n = 2), each with two biological replicates. + = tetracycline-induced clones. All experiments were performed with two
independently generated RNAi clones. ** p < 0.01,**** p < 0.0001, Mann–Withney test comparing NY-SM with RNAi
knock-down strains. ADKIN 3′-deoxytubercidin data was previously published [20].
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Figure 5. Susceptibility of 4EIP and 4E1 knockout cell lines to 5 (A) and compounds 1–4, and 6–9 (B). Results are expressed
as the mean IC50 (µM), and error bars represent SEM and are based on at least two independent experiments (n = 2),
each with two biological replicates. + = tetracycline-induced clones. **** p < 0.0001, Kruskal–Wallis test with Dunn’s
multiple comparison test.
3.4. 4 EIP but Not ADKIN Is Essential for In Vivo Infectivity in Mice
To evaluate the role of ADKIN and 4EIP, the impact of gene silencing on in vitro
growth and in vivo infectivity were determined. Knockdown of ADKIN did not alter para-
site growth in vitro and parasites retained a normal infectivity profile in mice (Figure 6A,B).
In contrast, 4EIP RNAi parasites showed a significant growth deficit already evident after
24 h of tetracycline induction (Figure 6C). In mice, knockdown of 4EIP was responsible for
a strikingly reduced infectivity (Figure 6D); however, the mice still succumbed to infection
within 2 weeks, most likely due to a loss of the RNAi phenotype in vivo. This hypothesis
was confirmed using 4EIP-KO parasites which could be detected during the first week of
infection but were undetectable from day 7 onwards until the pre-set endpoint of 70 dpi
(Figure 6E). Even after immunosuppressive treatment with 150 mg/kg cyclophosphamide,
parasitaemia did not reappear confirming the essential nature of 4EIP for in vivo infectivity.
Figure 6. Cont.
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Figure 6. The role of ADKIN and 4EIP in parasite growth and infectivity. Impact of ADKIN RNAi-mediated knockdown on
(A) in vitro growth and (B) and in vivo infectivity. Impact of 4EIP RNAi-mediated knockdown on (C) in vitro growth and
(D) and in vivo infectivity. (E) Impact of 4EIP knockout (4EIP-KO) and add-back (4EIP-AB) on in vivo infectivity. The arrow
indicates the moment of immunosuppressive treatment. Results are expressed as the average cell numbers, and error bars
represent the SEM. The in vitro experiments are based on two independent experiments (n = 2), each with two biological
replicates. + = tetracycline-induced clones; − = non-induced clones. The in vitro cumulative growth curves were performed
with two independently generated RNAi clones. * p < 0.01, *** p < 0.001, **** p < 0.0001.
3.5. 5 Does Not Specifically Impact Parasite Differentiation
Given the known involvement of 4EIP in parasite differentiation, the impact of 5 on
short stumpy differentiation was assessed. PAD1 protein expression was used as a stumpy-
specific marker using Western blot. To discern between the effects of changes in parasite
density as a result of the antiparasitic activity and 4EIP-specific compound effects on PAD1
expression, the impact of 5 was compared to that of 3′-deoxytubercidin, which is 4EIP-
independent. A concentration-dependent variation in PAD1 expression could be observed,
most likely dependent on parasite density instead of target-dependent effects, since the
same observations were made for 3′-deoxytubercidin (Figure 7). Additionally, no impact
was observed of compound addition to infectious blood meals on midgut infection ratios
in the tsetse fly vector (Figure 8).
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Figure 7. Western blot analysis for PAD1 expression. (A) PAD1 and EF1 protein expression (1: 4EIP-knockout, 2: untreated
controls, 3–5: 5-treated with IC50, IC50/2 and IC50/5 and 6–8: 3′-deoxytubercidin-treated with the IC50, IC50/2 and IC50/5).
(B) EF1-normalized area under the curve (AUC) values for PAD1. (C) Correlation between the normalized AUC values for
PAD1 and culture density at time of collection.
Figure 8. Impact of 5 supplementation on establishment of T. brucei in the tsetse fly midgut. Infectious blood meals were
supplemented with 5 or 3′-deoxytubercidin at the IC50. Results represent the percentage of G. m. morsitans flies with a
negative, low, or positive infection in the midgut and are a representation of two independent experiments with a minimum
of 25 flies per group.
4. Discussion
While limitations of currently used treatments for HAT should stimulate additional
drug discovery initiatives, it remains a challenge to identify non-toxic lead compounds
capable of crossing the BBB to treat stage-II infection. Since T. brucei parasites solely
depend on purine salvage, nucleoside analogues may offer opportunities as novel tools
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against HAT with CNS involvement [11]. Based on the previously identified nucleoside
analogues tubercidin and cordycepin with known antitrypanosomal potential, a range
of novel analogues were explored. The combination of structural elements of tubercidin
and cordycepin resulted in the discovery of 3′-deoxytubercidin as a highly interesting lead
compound to treat second-stage sleeping sickness [20]. 7-Deazaadenosines substituted
with phenyl groups or a pyridine ring resulted in excellent in vitro potency and selectivity
profile against African trypanosomes [19]. Finally, a series of 6-O-alkylated analogues was
highly promising with nanomolar in vitro activity against T. brucei parasites [21].
The occurrence of drug resistance in the field emphasizes the need for identification
of the potential mechanisms of resistance early on in the drug development process.
RNAi screening provides a whole-genome unbiased approach for the identification of
drug targets [28,46] and has been successfully used in identifying the MoA of the existing
antitrypanosomal drugs eflornithine and nifurtimox [26]. In the present study, we used
whole-genome RNAi screening to gain insight into the MoA of 5, whereby the involvement
of four targets, namely FLA1BP, EndoG, ADKIN and 4EIP, was demonstrated.
FLA1BP is responsible for joining the flagellar membrane to the cell membrane of
the parasite. RNAi knockdown of FLA1BP has been described to cause detachment of
the flagellum from the cell body, however, without any impact on parasite proliferation
rates [47]. The fact that FLA1BP is more abundantly found in procyclic cells than in BSF
may explain the inability to confirm this target and the lack of morphological changes in
our FLA1BP knockdown parasites.
EndoG plays a role in trypanolysis induced by the human serum apolipoprotein 1
(APOL1). Uptake of APOL1 by the parasite causes lysosomal and mitochondrial membrane
permeabilization and the subsequent translocation of mitochondrial EndoG to the parasite
nucleus causing DNA damage and cell death [42]. This target, however, could not be
confirmed, possibly due to experimental limitations.
ADKIN is a known enzyme in the purine salvage pathway of the parasite and is
responsible for the direct phosphorylation of adenosine to AMP following uptake of
the former [48,49]. The reduced sensitivity of ADKIN RNAi strains to 5 suggests the
occurrence of compound phosphorylation upon uptake by the parasite. This phenomenon
has already been described for other nucleoside analogues [20]. However, the fact that 5
remained active against the ADKIN knockdown strains at sub-micromolar levels indicates
that this phosphorylation may not be essential or only partially contributes to the overall
activity. It is clear from a broader compound evaluation on the developed ADKIN RNAi
strains that various analogues exhibit different degrees of dependency on ADKIN or
may be subject to different rates of enzymatic conversion by ADKIN. ADKIN plays an
important role in trypanosomal purine salvage [48,49], but the in vitro and in vivo growth
curves [50,51] reveal that it is not essential for growth and infectivity. This can be attributed
to the fact that loss of ADKIN activity redirects adenosine salvage through the alternative
cleavage-dependent pathway. Additionally, the parasite can salvage hypoxanthine, inosine,
and adenine to form all of its required purines [48].
The second identified target, 4EIP, has been extensively studied in Leishmania ma-
jor. 4EIP binds with its N-terminal domain to the mRNA cap-binding protein LeishIF4E,
leading to dissociation from the cap and a suppression of active translation [52]. Simi-
lar binding properties and functions were later described for African trypanosomes [35].
The MoA of 5 can be partially attributed to 4EIP as confirmed by the use of knock-out and
add-back control parasites. However, the cap-binding protein 4E1 was not influenced by
5, indicating that the inhibition of 4EIP works independently of 4E1. The suppression of
translation in T. brucei, as regulated by 4EIP, is required for successful differentiation into
short stumpy parasites in the bloodstream. This is an essential adaptation of the parasite
for successful transmission to the tsetse fly vector [35] and subsequent transformation
to procyclic parasites in the tsetse fly midgut. In this study, we showed a large growth
deficit of 4EIP knockdown parasites in culture conditions, while in mice, 4EIP knockout
led to a rapid clearance of parasite burdens. The underlying basis for the essential role of
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4EIP in vivo remains to be elucidated and this study could not demonstrate a link between
compound activity and inhibition of parasite differentiation in vitro and in the tsetse fly.
In summary, we here describe the acquired insights in the MoA of novel 7-deazaadenosine
nucleoside analogues for the treatment of HAT. RNAi screening in combination with confir-
matory in vitro and in vivo experiments using knockout strains identified the involvement
of 4EIP in the activity of some antitrypanosomal nucleoside analogues. The reliance of some
compounds on this gene product and the essential nature for in vivo infectivity indicate that
4EIP represents a potential drug target. The available RNAi and knockout clones will allow
a more in depth analysis of the structural requirements for metabolic activation and 4EIP
interaction of newly synthetized nucleoside analogues.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/microorganisms9040826/s1, Supplementary method S1: Synthesis of compound 4, Figure
S1: Overview of the RNAi screening protocol. (A) Experimental overview of the screening protocol
of RNAi libraries for compound 5. (B) Graphic representation of the P2T7Bern vector [25], Table S1:
Overview of the used primers, Table S2: Sequencing results of the RNAi inserts.
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